A 7-day continuous infusion of PTH or PTHrP suppresses bone formation and uncouples bone turnover

Journal of Bone and Mineral Research

Volumn 26, Issue 9, 2011, Pages 2287-2297

  Horwitz, Mara J ^a   Tedesco, Mary Beth ^a   Sereika, Susan M ^b   Prebehala, Linda ^a   Gundberg, Caren M ^c   Hollis, Bruce W ^d   Bisello, Alessandro ^a   Garcia Ocaña, Adolfo ^a   Carneiro, Raquel M ^a   Stewart, Andrew F ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

HUMORAL HYPERCALCEMIA OF MALIGNANCY; HYPERPARATHYROIDISM; LACTATION; PARATHYROID HORMONE; PTH RELATED PROTEIN

Indexed keywords

CALCITRIOL; CALCIUM; PARATHYROID HORMONE; PARATHYROID HORMONE DERIVATIVE; PARATHYROID HORMONE RELATED PROTEIN; PARATHYROID HORMONE[1-34]; PHOSPHORUS;

ADULT; ARTICLE; BONE TURNOVER; CALCIUM BLOOD LEVEL; CALCIUM MOBILIZATION; CELL MATURATION; CLINICAL ARTICLE; CONTINUOUS INFUSION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; FEMALE; HUMAN; HUMAN EXPERIMENT; HYPERCALCEMIA; HYPERCALCIURIA; IN VIVO STUDY; LACTATION; MALE; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS;

ADULT; BIOLOGICAL MARKERS; BONE REMODELING; BONE RESORPTION; CALCITRIOL; CALCIUM; DEMOGRAPHY; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; IONS; KIDNEY; MALE; MINERALS; OSTEOGENESIS; PARATHYROID HORMONE; PARATHYROID HORMONE-RELATED PROTEIN; PHOSPHORUS; TIME FACTORS; YOUNG ADULT;

EID: 80051958406     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.415     Document Type: Article

References (44)

1. Nissenson RA, Juppner H,. Parathyroid hormone. In:, Rosen CJ, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 7th ed. Washington, DC: American Society for Bone and Mineral Research; 2008: 123-126.
2. Wu T, Vasavada R, Yang K, et al. Structural and physiologic characterization of the mid-region secretory form of PTHrP. J Biol Chem. 1996; 271: 24371-24381. (Pubitemid 26333168)
3. Juppner H, Gardella TJ, Brown EM, Kronenberg HM, Potts JT,. Parathyroid hormone and parathyroid hormone-related peptide in the regulation of calcium homeostasis and bone development. In:, DeGroot L, ed. Endocrinology. 5th ed. Philadelphia: Elsevier Saunders; 2006: 1377-1417.
4. Dean T, Vilardaga JP, Potts JT, Gardella TJ,. Altered selectivity of parathyroid hormone (PTH) and PTH-related protein (PTHrP) for distinct conformations of the PTH/PTHrP receptor. Mol Endocrinol. 2008; 22: 156-166.
5. Wysolmerski JJ,. Parathyroid hormone-related protein. In:, Rosen CJ, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 7th ed. Washington, DC: American Society for Bone and Mineral Research; 2008: 127-133.
6. Kovacs CS, Kronenberg HM,. Maternal-fetal calcium and bone metabolism during pregnancy, puerperium, and lactation. Endocr Rev. 1997; 18: 832-872. (Pubitemid 28009569)
7. Stewart AF, Broadus AE,. Malignancy-associated hypercalcemia. In:, DeGroot L, Jameson LJ, eds. Endocrinology. 5th ed. Philadelphia: W.B. Saunders; 2006: 1555-1565.
8. Stewart AF, Horst R, Deftos LJ, Cadman EC, Lang R, Broadus AE,. Biochemical evaluation of patients with cancer-associated hypercalcemia: evidence for humoral and non-humoral groups. N Engl J Med. 1980; 303: 1377-1383. (Pubitemid 11197525)
9. Stewart AF, Vignery A, Silvergate A, et al. Quantitative bone histomorphometry in humoral hypercalcemia of malignancy: uncoupling of bone cell activity. J Clin Endo Metab. 1982; 55: 219-227. (Pubitemid 13238718)
10. Nakayama K, Fukumoto S, Takeda S, et al. Differences in bone and vitamin D metabolism between primary hyperparathyroidism and malignancy-associated hypercalcemia. J Clin Endocrinol Metab. 1996; 81: 607-611. (Pubitemid 26055672)
11. Kalkwarf HJ, Specker BL, Bianchi DC, Ranz J, Ho M,. The effect of calcium supplementation on bone density during lactation and after weaning. N Engl J Med. 1997; 337: 523-528. (Pubitemid 27352018)
12. Silverberg SJ, Bilezikian JP,. Primary Hyperparathyroidism. In:, Rosen CJ, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 7th ed. Washington, DC: American Society for Bone and Mineral Research; 2008: 302-306.
13. Silverberg SJ, Bilezikian JP,. Primary Hyperparathyroidism. In:, DeGroot L, ed. Endocrinology. 5th ed. Philadelphia: W.B. Saunders; 2006: 1533-1554.
14. Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezkian JP,. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med. 2000; 341: 1249-1255.
15. Everhart-Caye M, Inzucchi SE, Guinness-Henry J, Mitnick MA, Stewart AF,. Parathyroid hormone-related protein(1-36) is equipotent with parathyroid hormone(1-34) in humans. J Clin Endocrinol Metab. 1996; 81: 199-208.
16. Syed MA, Horwitz MJ, Tedesco MB, Garcia-Ocaña A, Wisniewski SR, Stewart AF,. Parathyroid hormone-related protein (1-36) stimulates renal tubular calcium reabsorption in normal human volunteers: implications for the pathogenesis of humoral hypercalcemia of malignancy. J Clin Endocrinol Metab. 2001; 86: 1525-1531. (Pubitemid 32374898)
17. 2 vitamin D concentrations and fractional calcium excretion in healthy human volunteers. J Clin Endocrinol Metab. 2003; 88: 1603-1609. (Pubitemid 36623376)
18. 2 vitamin D and prolonged suppression of bone formation. J Bone Min Res. 2005; 20: 1792-1803. (Pubitemid 41361880)
19. Simon LS, Slovik Dm, Neer RM, Krane SM,. Changes in serum levels of type I and III procollagen extension peptides during infusion of human parathyroid hormone fragment (1-34). J Bone Miner Res. 1988; 3: 241-246.
20. Leder BZ, Smith MR, Fallon MA, Lee M-LT, Finkelstein JS,. Effects of gonadal steroid suppression on skeletal sensitivity to parathyroid hormone in men. J Clin Endocrinol Metab. 2001; 86: 511-516. (Pubitemid 32207452)
21. Cosman F, Shen V, Fang X, Seibel M, Ratcliffe A, Lindsay R,. Estrogen protection against bone-resorbing effects of parathyroid hormone infusion: assessment by use of biochemical markers. Ann Int Med. 1993; 118: 337-343. (Pubitemid 23070617)
22. Slovik DM, Adams JS, Neer RM, Holick MF, Potts JT,. Deficient production of 1,25-Dihydroxyvitamin D in elderly osteoporotic patients. N Engl J Med. 1981; 305: 372-374. (Pubitemid 11063752)
23. Stewart A, Mangin M, Wu T, et al. A synthetic human parathyroid hormone-like protein stimulates bone resorption and causes hypercalcemia in rats. J Clin Invest. 1988; 81: 596-600. (Pubitemid 18075256)
24. Henry JG, Mitnick MA, Dann PR, Stewart AF,. Parathyroid hormone-related protein(1-36) is biologically active when administered subcutaneously to humans. J Clin Endocrinol Metab. 1997; 82: 900-906. (Pubitemid 27106609)
25. Plotkin H, Gundberg C, Mitnick M, Stewart AF,. Dissociation of bone formation from resorption during two-week treatment with hPTHrP(1-36) in humans: potential as an anabolic therapy for osteoporosis. J Clin Endocrinol Metab. 1998; 83: 2786-2791. (Pubitemid 28493777)
26. Hollis BW, Kamerud JQ, Kurkowski A, Beaulieu J, Napoli JL,. Quantification of circulating 1,25(OH)2D by RIA with an 125-I-labled tracer. Clin Chem. 1996; 42: 586-592.
27. Cosman F, Shen V, Herrington B, Lindsay R,. Response of the parathyroid gland to infusion of human parathyroid hormone (1-34): demonstration of suppression of endogenous secretion using immunoradiometric intact PTH-(1-84) assay. J Clin Endocrinol Metab. 1991; 73: 1345-1351. (Pubitemid 121000714)
28. Cosman F, Greenspan SL,. Parathyroid hormone treatment for osteoporosis. In:, Rosen CJ, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 7th ed. Washington, DC: American Society for Bone and Mineral Research; 2008: 244-249.
29. Hodsman AB, Fraher LJ, Ostbye T, Adachi JD, Steer BM,. An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis. J Clin Inves. 1993; 91: 1138-1148. (Pubitemid 23095292)
30. Dobnig H, Turner RH,. Effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology. 1997; 138: 4607-4612. (Pubitemid 27460894)
31. van der Horst G, Farih-Sips H, Lowik CW, Karperien M,. Multiple mechanisms are involved in inhibition of osteoblast differentiation by PTHrP and PTH in KS483 Cells. J Bone Miner Res. 2005; 20: 2233-2244. (Pubitemid 41698786)
32. Ishizuya T, Yokose S, Hori M, Noda T, Suda T, Yoshiki S,. Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells. J Clin Invest. 1997; 99: 2961-2970. (Pubitemid 27278673)
33. Wang YH, Liu Y, Buhl K, Rowe DW,. Comparison of the action of transient and continuous PTH on primary osteoblast cultures expressing differentiation stage-specific GFP. J Bone Miner Res. 2005; 20: 5-14. (Pubitemid 41716213)
34. Lotinun S, Sibonga JD, Turner RT,. Evidence that the cells responsible for marrow fibrosis in a rat model of hyperparathyroidism are pre-osteoblasts. Endocrinology. 2005; 146: 4074-4081. (Pubitemid 41175779)
35. Sowers M, Eyre D, Hollis BW, et al. Biochemical markers of bone turnover in lactating and nonlactating postpartum women. J Clin Endocrinol Metab. 1995; 80: 2210-2216.
36. Csaba M, Bhattoa HP, Bettembuk P, Balogh A,. The effects of pregnancy and lactation on hormonal status and biochemical markers of bone turnover. Eur J Obstet Gynecol Reprod Biol. 2003; 106: 209-213. (Pubitemid 36120473)
37. Kalkwarf HJ, Specker BL, Ho M,. Effects of calcium supplementation on calcium homeostasis and bone turnover in lactating women. J Clin Endocrinol and Metab. 1999; 84: 464-470. (Pubitemid 29075670)
38. Cross NA, Hillman LS, Allen SH, Krause GF,. Changes in bone mineral density and markers of bone remodeling during lactation and postweaning in women consuming high amounts of calcium. J Bone Miner Res. 1995; 10: 1312-1320.
39. Dempster DW, Parisien M, Silverbrg SJ, et al. On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism. J Clin Endocrinol Metab. 1999; 84: 1562-1566. (Pubitemid 30644254)
40. Prank K, Nowlan SJ, Harms HM, Kloppstech M, Brabant G,. Hesch R-D. Time series prediction of parathyroid hormone concentration. J Clin Invest. 1995; 95: 2910-2919.
41. Schmitt CP, Obry J, Feneberg R, et al. Beta adrenergic blockade augments pulsatile PTH secretion in humans. JASN. 2003; 14: 3245-3250. (Pubitemid 37509300)
42. Chapotot F, Gronfier C, Speigel K, Luthringer R, Brandenberger G,. Relationships between intact PTH and 24-hour profiles, sleep-wake cycle, and sleep electroencephalographic activity in man. J Clin Endocrinol Metab. 1996; 81: 3759-3765. (Pubitemid 26339951)
43. Cauley JA, Palermo L, Vogt M, et al. Prevalent verbral fractures in black women and white women. J Bone Miner Res. 2008; 23: 1458-1467.
44. Cosman F, Nieves J, Dempster D, Lindsay T,. Vitamin D economy in blacks. J Bone Miner Res. 2007; 22 (Suppl 2): v34-38. (Pubitemid 351304646)